CY1110256T1 - Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου - Google Patents

Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου

Info

Publication number
CY1110256T1
CY1110256T1 CY20091100289T CY091100289T CY1110256T1 CY 1110256 T1 CY1110256 T1 CY 1110256T1 CY 20091100289 T CY20091100289 T CY 20091100289T CY 091100289 T CY091100289 T CY 091100289T CY 1110256 T1 CY1110256 T1 CY 1110256T1
Authority
CY
Cyprus
Prior art keywords
transmissional
liggin
antigen
cycle
lectin
Prior art date
Application number
CY20091100289T
Other languages
English (en)
Inventor
Daniel E H Afar
Rene S Hubert
Aya Jakobovits
Arthur B Raitano
Original Assignee
Agensys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys, Inc. filed Critical Agensys, Inc.
Publication of CY1110256T1 publication Critical patent/CY1110256T1/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Περιγράφεται καινοφανές γονίδιο (καλούμενο PC-LECTIN), εντόνως υπερεκφραζόμενο σε καρκίνο στον προστάτη και η κωδικοποιούμενη πρωτεΐνη του. To PC-LECTIN σε φυσιολογικούς ιστούς ανθρώπου περιορίζεται στους όρχεις, αλλά εκφράζεται εντόνως σε καρκίνο στον προστάτη. Συνεπώς, το PC-LECTIN παρέχει ένα διαγνωστικό και/ή θεραπευτικό στόχο έναντι του καρκίνου στον προστάτη.
CY20091100289T 1999-08-12 2009-03-16 Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου CY1110256T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14893599P 1999-08-12 1999-08-12
EP00953992A EP1200590B1 (en) 1999-08-12 2000-08-11 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof

Publications (1)

Publication Number Publication Date
CY1110256T1 true CY1110256T1 (el) 2015-01-14

Family

ID=22528098

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20091100289T CY1110256T1 (el) 1999-08-12 2009-03-16 Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
CY20111100104T CY1111147T1 (el) 1999-08-12 2011-01-31 Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY20111100104T CY1111147T1 (el) 1999-08-12 2011-01-31 Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου

Country Status (13)

Country Link
US (6) US6602501B1 (el)
EP (2) EP1992695B1 (el)
JP (3) JP4373637B2 (el)
AT (2) ATE420175T1 (el)
AU (5) AU774436B2 (el)
CA (1) CA2380550C (el)
CY (2) CY1110256T1 (el)
DE (2) DE60041333D1 (el)
DK (2) DK1200590T3 (el)
ES (2) ES2355428T3 (el)
IL (3) IL147902A0 (el)
PT (2) PT1200590E (el)
WO (1) WO2001012811A1 (el)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DK1609863T3 (da) * 1999-03-23 2008-12-15 Genentech Inc Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
AU2005205755B2 (en) * 1999-03-23 2007-10-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1046651A1 (en) * 1999-04-19 2000-10-25 Koninklijke Universiteit Nijmegen Composition and method for modulating dendritic cell-T interaction
ATE420175T1 (de) 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
US7842458B2 (en) 1999-08-12 2010-11-30 Agensys, Inc. Nucleic acids and corresponding proteins entitled 58P1D12 useful in treatment and detection of cancer
US7449548B2 (en) * 2001-12-07 2008-11-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 193P1E1B useful in treatment and detection of cancer
TW200413725A (en) * 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2006022722A1 (en) * 2004-08-16 2006-03-02 Agensys, Inc. Nucleic acids and corresponding proteins entitled 58p1d12 useful in treatment and detection of cancer
WO2007001448A2 (en) * 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
GB0426822D0 (en) * 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
GB0426823D0 (en) 2004-12-07 2005-01-12 Precisense As Sensor for detection of glucose
WO2007070682A2 (en) * 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
WO2008105773A2 (en) 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
WO2007133807A2 (en) 2006-05-15 2007-11-22 Massachusetts Institute Of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20100303723A1 (en) * 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP2134830A2 (en) * 2007-02-09 2009-12-23 Massachusetts Institute of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
WO2008124639A2 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
EP2394657A1 (en) 2007-10-12 2011-12-14 Massachusetts Institute Of Technology Vaccine nanotechnology
WO2010022279A1 (en) * 2008-08-20 2010-02-25 Agensys, Inc. Antibodies and related molecules that bind to 58p1d12 proteins
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8591905B2 (en) * 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
CN105238781B (zh) * 2015-11-06 2018-02-16 福建省农业科学院果树研究所 基于转录组序列开发的李ssr标记引物对及其应用
US10792378B2 (en) 2017-04-28 2020-10-06 Medtronics Minimed, Inc. Using a blue-shifted reference dye in an optical glucose assay
US10543288B2 (en) 2017-04-28 2020-01-28 Medtronic Minimed, Inc. Modified-dextrans for use in optical glucose assays

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US4975287A (en) 1989-09-01 1990-12-04 Wm. Wrigley Jr. Company Gum composition containing protein macrocolloids
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
ATE325813T1 (de) 1990-06-27 2006-06-15 Univ Princeton Proteinkomplex p53/p90
US5733731A (en) 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
US5879898A (en) * 1992-11-20 1999-03-09 Isis Innovation Limited Antibodies specific for peptide corresponding to CD44 exon 6, and use of these antibodies for diagnosis of tumors
CH686982A5 (fr) 1993-12-16 1996-08-15 Maurice Stroun Méthode pour le diagnostic de cancers.
DK0773952T3 (da) 1994-07-20 2004-03-22 Inst Genetics Llc Interaktionsfældesystemer til påvisning af proteininteraktioner
US5919652A (en) 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US5681923A (en) * 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
US6476192B1 (en) * 1996-04-15 2002-11-05 Nicola C. Lally Recombinant antigens useful for the serodiagnosis of neosporosis
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
US5928868A (en) 1996-04-26 1999-07-27 Massachusetts Institute Of Technology Three hybrid screening assay
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
EP0953039B1 (en) 1996-10-15 2007-08-29 The Regents Of The University Of California Animal models of human prostate cancer progression
US5846722A (en) 1996-10-16 1998-12-08 Terrapin Technologies, Inc. System to detect small molecule/peptide interaction
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US20030004311A1 (en) 1997-06-18 2003-01-02 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7435793B2 (en) 1998-05-15 2008-10-14 Genentech, Inc. Peptides that induce chondrocyte redifferentiation
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030087344A1 (en) * 1997-06-18 2003-05-08 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030022239A1 (en) 1997-06-18 2003-01-30 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030166104A1 (en) 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030032101A1 (en) 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7160985B2 (en) 1997-10-29 2007-01-09 Genentech, Inc. Pro180 polypeptide
US7125959B2 (en) 1998-05-15 2006-10-24 Genentech, Inc. PRO4405 polypeptides
JP2002517185A (ja) 1998-06-01 2002-06-18 アジェンシス，インコーポレイテッド 前立腺癌および結腸癌の診断および治療に有用な腫瘍抗原
CA2339301A1 (en) 1998-07-30 2000-02-10 Human Genome Sciences, Inc. Hdpbo81 nucleic acids and polypeptides
US20030050465A1 (en) 1998-08-10 2003-03-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000039296A1 (en) 1998-12-23 2000-07-06 Immunex Corporation Lectin s3939 dna and polypeptides
US7465785B2 (en) 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
DK1609863T3 (da) 1999-03-23 2008-12-15 Genentech Inc Udskilte polypeptider og transmembranpolypeptider samt nucleinsyrer kodende for disse
EP1074617A3 (en) 1999-07-29 2004-04-21 Research Association for Biotechnology Primers for synthesising full-length cDNA and their use
ATE420175T1 (de) 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
US7555263B1 (en) * 1999-10-21 2009-06-30 Broadcom Corporation Adaptive radio transceiver
US7300758B2 (en) 1999-12-09 2007-11-27 Genetech, Inc. Nucleic acid underexpressed in esophageal tumor
CN1316009C (zh) * 2000-03-21 2007-05-16 三菱丽阳株式会社 微生物的培养方法
US20030100497A1 (en) 2001-06-20 2003-05-29 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
JP3921367B2 (ja) * 2001-09-26 2007-05-30 日本電気株式会社 データ処理装置および方法、コンピュータプログラム、情報記憶媒体、並列演算装置、データ処理システム
US7202335B2 (en) * 2001-12-06 2007-04-10 Genentech, Inc. PRO300 polypeptides
JP2004187620A (ja) 2002-12-13 2004-07-08 Sumitomo Pharmaceut Co Ltd 腎疾患の疾患マーカーおよびその利用
US20090068098A1 (en) 2007-08-20 2009-03-12 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins

Also Published As

Publication number Publication date
JP4373637B2 (ja) 2009-11-25
AU774436B2 (en) 2004-06-24
IL147902A0 (en) 2002-08-14
DE60041333D1 (de) 2009-02-26
US20100028374A1 (en) 2010-02-04
US7087718B2 (en) 2006-08-08
DE60045201D1 (de) 2010-12-16
AU2009200299B2 (en) 2011-12-22
JP2003507042A (ja) 2003-02-25
AU2006203476A1 (en) 2006-08-31
ATE420175T1 (de) 2009-01-15
IL147902A (en) 2011-04-28
CA2380550C (en) 2011-02-01
US8022174B2 (en) 2011-09-20
US20040265898A1 (en) 2004-12-30
US7598045B2 (en) 2009-10-06
AU2009200299A1 (en) 2009-02-19
AU6635100A (en) 2001-03-13
PT1992695E (pt) 2011-01-12
JP2009235109A (ja) 2009-10-15
EP1992695B1 (en) 2010-11-03
ES2317846T3 (es) 2009-05-01
EP1200590A1 (en) 2002-05-02
IL197988A (en) 2011-12-29
ES2355428T3 (es) 2011-03-25
CA2380550A1 (en) 2001-02-22
US6602501B1 (en) 2003-08-05
DK1992695T3 (da) 2011-02-14
AU2004203513A1 (en) 2004-08-26
AU2004203513B2 (en) 2006-05-11
CY1111147T1 (el) 2015-06-11
US7153940B2 (en) 2006-12-26
EP1992695A2 (en) 2008-11-19
US7148337B2 (en) 2006-12-12
AU2009200576A1 (en) 2009-03-05
WO2001012811A1 (en) 2001-02-22
DK1200590T3 (da) 2009-03-16
PT1200590E (pt) 2009-03-24
US20040038271A1 (en) 2004-02-26
JP2006204306A (ja) 2006-08-10
US20050019872A1 (en) 2005-01-27
ATE486938T1 (de) 2010-11-15
EP1200590B1 (en) 2009-01-07
US20070092918A1 (en) 2007-04-26
AU2009200576B2 (en) 2011-12-22
EP1992695A3 (en) 2009-01-07

Similar Documents

Publication Publication Date Title
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
CY1110029T1 (el) Γονιδιο που εκφραζεται στον καρκινο του προστατη
CY1109125T1 (el) Θεραπευτικα και διαγνωστικα anti-hsp 70 αντισωματα
TNSN05300A1 (en) Treatment with anti-vegf antibodies
CY1110134T1 (el) Αντισωματα ειδικα για το cd22 και η θεραπευτικη και διαγνωστικη χρηση τους
ATE305313T1 (de) Radiotherapy
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
PT1349870E (pt) Composições para a terapêutica e diagnóstico do cancro do ovário
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
DE50002293D1 (de) Verwendung von csf-1-inhibitoren
WO2004000094A3 (en) Predictive markers in cancer therapy
CY1115407T1 (el) Θοριο-227 για χρηση στην ακτινοθεραπεια ασθενειων των μαλακων ιστων
CY1109868T1 (el) Cd81 πρωτεϊνη υποδοχεας ηπατιτιδας c
MXPA05003818A (es) Perfilamiento de la expresion genica de muestras ffpe.
WO2003070889A3 (en) Prostate specific genes and the use thereof in design or therapeutics
CY1109029T1 (el) Νουκλεϊνικο οξυ και αντιστοιχη πρωτεϊνη ονομαζομενη 85p1b3 χρησιμα στην αγωγη και τον εντοπισμο του καρκινου
IT1307864B1 (it) Metodo diagnostico per il riconoscimento di neoplasie umane attraversola determinazione dell'isoforma ctn-c della tn-c, frammenti di
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
ATE501255T1 (de) 84p2a9: prostata- und hodenspezifisches protein, das sehr stark bei prostatakrebs vorkommt
CY1108412T1 (el) Συνθεσεις εμβολιου που περιλαμβανουν omp85 πρωτεϊνες απο neisseria gonorrhoea και neisseria miningitidis
ATE383154T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
ATE527282T1 (de) Tumor assoziierte antigene